Anti-apolipoprotein A-1 autoantibodies as risk biomarker for cardiovascular diseases in type 2 diabetes mellitus

El-Lebedy, Dalia; Rasheed, Enas Abdel; Kafoury, Mona; Haleem, Dalia A. Abd-El; Awadallah, Eman; Ashmawy, Ingy

doi:10.1016/j.jdiacomp.2016.02.014

Cited by 32 publications

(31 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, 11 autoantibodies were identified using a high-density protein microarray among type 2 diabetic subjects in which the estimated prevalence was highest for autoantibodies to transaldolase-1 and mitochondrial ribosomal protein S7 (79% and 40%, respectively). 21 In addition, autoantibodies to DNA–advanced glycation end product 22 and apolipoprotein A-1 23 and B-100 24 have also been detected. Among these, anti−apolipoprotein A-1 autoantibodies were present in up to 36% of patients with type 2 diabetes and cardiovascular disease.…”

Section: Discussionmentioning

confidence: 99%

“…Among these, anti−apolipoprotein A-1 autoantibodies were present in up to 36% of patients with type 2 diabetes and cardiovascular disease. 23 Although the detailed pathogenic mechanisms underlying the development of autoantibodies remain to be investigated, anti-EPOR antibodies might be additional autoantibodies that could be present in patients with type 2 diabetes and CKD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD

Hara

Furuichi

Koshino

et al. 2018

Kidney International Reports

View full text Add to dashboard Cite

IntroductionWe examined the impact of autoantibodies on the erythropoietin receptor (EPOR) in type 2 diabetic patients with chronic kidney disease (CKD).MethodsA total of 112 Japanese patients with type 2 diabetes who had CKD were enrolled in this study and followed for a mean of 45 months. Sera from these patients were screened for anti-EPOR antibodies using enzyme-linked immunosorbent assays.ResultsAnti-EPOR antibodies were detected in 26 patients (23%). Anti-EPOR antibodies were associated with low hemoglobin concentrations and decreased renal function. In patients with biopsy-proven diabetic nephropathy, anti-EPOR antibodies were associated with increased levels of interstitial inflammation. A decrease in renal function was observed more frequently in patients with antibodies than in those without antibodies, and the presence of the antibodies together with well-known clinical parameters, including proteinuria and low glomerular filtration rate, was a significant risk factor for end-stage renal disease. In human tubular epithelial HK-2 cells, IgG fractions containing anti-EPOR antibodies upregulated the expression of monocyte chemoattractant protein-1 mRNA under a high concentration of glucose.ConclusionAnti-EPOR antibodies might be involved in the progression of renal lesions and in the impaired erythropoiesis in type 2 diabetic patients with CKD. Furthermore, the presence of anti-EPOR antibodies may be an additional predictor for end-stage renal disease in type 2 diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD

Hara

Furuichi

Koshino

et al. 2018

Kidney International Reports

View full text Add to dashboard Cite

show abstract

“…In patients with rheumatoid arthritis anti-apoA-1 IgG positivity was 17% and was associated with a higher incidence of major cardiovascular events [9]. In a recent study in type 2 diabetes the incidence of autoantibodies to apoA-1 was 37.5% in patients with cardiovascular disease (CVD) and patients who were autoantibody positive showed 5.7 times increased CVD risk [10]. Anti-apoA-I IgG is thus recognised as an independent predictor of poor cardiovascular outcome in several different populations at risk for CVD with and without concomitant autoimmune disease and provides incremental prognostic information over traditional risk factors for CVD [20].…”

Section: Discussionmentioning

confidence: 99%

Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?

Bridge

Pagano²,

Jones

et al. 2018

Journal of Hepatology

View full text Add to dashboard Cite

Background/purpose One to three per cent of the world's population has hepatitis C virus (HCV) infection, which is not only a major cause of liver disease and cancer but also associated with an increased risk of atherosclerosis, despite an ostensibly favourable lipid profile. Autoantibodies are frequent in HCV infection and emerging evidence shows that autoantibodies could be valuable for cardiovascular disease (CVD) risk stratification. This study investigated a novel independent biomarker of CVD, autoantibodies to apolipoprotein A-1 (anti-apoA-1 IgG) and lipids in patients with chronic HCV before, during and after direct-acting anti-viral (DAA) therapy. Methods Eighty-nine blinded serum samples from 27 patients with advanced chronic HCV were assayed for lipids and anti-apoA-1 IgG by ELISA. Results Pre-treatment HCV viral load correlated with high-density lipoprotein cholesterol (HDL-C, r = 0.417; p = 0.042) and negatively with apolipoprotein (apo)B (r =-0.497; p = 0.013) and markers of CVD risk, the apoB/apoA-1 ratio (r =-0.490; p = 0.015) and triglyceride level (TG)/HDL-C ratio (r =-0.450; p = 0.031). Fourteen (52%) of 27 patients had detectable anti-apoA-1 IgG autoantibodies pre-treatment; only two became undetectable with virological cure. Autoantibody-positive sera had lower apoA-1 (p = 0.012), HDL-C (p = 0.009) and total cholesterol (p = 0.006) levels. Conclusions This is the first report of the presence of an emerging biomarker for atherosclerosis, anti-apoA-1 IgG, in some patients with HCV infection. It may be induced by apoA-1 on the surface of HCV lipoviral particles. The autoantibodies inversely correlate with apoA-1 and HDL levels and may render HDL dysfunctional. Whether these hypothesis-generating findings have clinical implications in HCV patients requires further study.

show abstract

“…109 Finally, type 2 diabetic patients who were positive for ApoA1 antibodies also had significantly higher cardiovascular risk compared with ApoA1 IgG-negative diabetic subjects thereby indicating that anti-apoA-1 IgG is a cardiovascular risk biomarker in diabetic patients. 110 The presence of anti-HDL antibodies was recently reported. 111,112 However, it is unknown whether anti-HDL antibodies are similar to anti-ApoA1 IgG or represent a different entity.…”

Section: Proatherogenic Functional Effects Of Antiapoa1 Self-antibodimentioning

confidence: 92%

ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease

Chistiakov

Orekhov

Bobryshev

2016

Laboratory Investigation

View full text Add to dashboard Cite

Anti-apolipoprotein A-1 autoantibodies as risk biomarker for cardiovascular diseases in type 2 diabetes mellitus

Cited by 32 publications

References 51 publications

Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD

Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD

Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?

ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease

Contact Info

Product

Resources

About